Scholarlink

Purpose <p>Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres.</p> Methods <p>We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery.</p> Results <p>A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; <i>p</i> &lt; 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; <i>p</i> = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models.</p> Conclusion <p>The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Andreas Ziebart,
  • Julia Onken,
  • Minou Nadji-Ohl,
  • Christine Jungk,
  • Stefan Rückriegel,
  • Dorothee Mielke,
  • Rüdiger Gerlach,
  • Marie-Therese Forster,
  • Constantin Roder,
  • Katja Kniese,
  • Nicolas Neidert,
  • Ludovica Fabbrocini,
  • Darius Kalasauskas,
  • Gerges Aziz,
  • Sabrina Riehl,
  • Lennart Sannwald,
  • Benjamin Mayer,
  • Christian Rainer Wirtz,
  • Daniel Sachs,
  • Sebastian Ille,
  • Mario Löhr,
  • Rainer Ritz,
  • Florian Ringel,
  • Florian Ebner,
  • Roland Roelz,
  • Jürgen Beck,
  • Arya Nabavi,
  • Marcos Tatagiba,
  • Marcus Czabanka,
  • Veit Rohde,
  • Ralf-Ingo Ernestus,
  • Sandro Krieg,
  • Oliver Ganslandt,
  • Peter Vajkoczy,
  • Jan Coburger

摘要

Purpose

Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres.

Methods

We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery.

Results

A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models.

Conclusion

The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.